Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA

Adjuvanted RSVPreF3 demonstrated an effectiveness of over 80% against laboratory-confirmed RSV in a real-world study conducted in the USA. 

Dr Hung Fu Tseng (Kaiser Permanente Southern California, CA, USA) presented a test-negative study using electronic health records from 9 hospitals in the Kaiser Permanente Southern California network, which administered adjuvanted RSVPreF3 [1]. Data were analysed from individuals aged ≥60 years who were hospitalised for lower respiratory tract disease. An RSV quantitative reverse transcription polymerase chain reaction (RT-qPCR) specimen was collected between 7 days before and 2 days after hospital admission, from December 2023 to February 2025. RSV-negative controls for vaccine effectiveness calculations were matched by age, sex, race and ethnicity, admission year/month, and immunocompromised status. 

In total, 281 RSV-positive cases and 1,108 controls were included, of whom 2.6% of cases and 13.7% of controls had received adjuvanted RSVPreF3 vaccination within the same season. Among these patients, the real-world vaccine effectiveness was 82.3% (95% CI 61.5–91.9). Effectiveness estimates exceeded 80% across all assessed subgroups, including those with immunocompromised status (yes/no), age at infection (60-74 and ≥75 years), and comorbidities such as kidney disease, diabetes, heart disease, lung disease, and cardiopulmonary disease. 

The authors concluded that “early results from the adjuvanted RSVPreF3 vaccine effectiveness study, covering December 2023 to February 2025, show a high vaccine effectiveness of 82.3% in preventing laboratory-confirmed RSV lower respiratory tract disease hospitalisations among adults ≥60 years, including those at increased risk of severe RSV disease.” Further results are expected with longer follow-up across additional seasons. 

1. Tseng HF, et al. Real-world effectiveness of adjuvanted RSVPreF3 vaccine in preventing RSV-associated lower respiratory tract disease (LRTD) hospitalisation in adults aged ≥60 years: early results of a test-negative design study. 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal. 

Copyright ©2025 Medicom Publishing Group



Posted on 21 October 202521 October 2025